TECHNOLOGY SUMMARY

The biological function of protein-­based therapeutics are determined by the three dimensional structure of the molecule. Therefore, it is imperative to analyze the structure of protein therapeutics at several stages of the drug development process to ensure both safety and efficacy of the drug. Biopharmaceutical manufacturers are required to demonstrate the consistency of the protein structure to the FDA. Current techniques for protein structural characterization are slow, expensive and difficult to perform. We have developed a technology called Plasma Induced Modification to Biomolecules (PLIMB) that addresses the need of the industry for routine structural analysis of proteins. A way to quickly and efficiently analyze higher order structures of proteins on a benchtop scale, PLIMB will enable faster development of protein therapeutics, throughout the drug discovery process. Ultimately, PLIMB will enable fast, high resolution structural analysis of proteins, a capability which is highly sought after in the pharmaceutical industry.

AREA/MATURITY/AWARDS

Primary Application Area: Biotech, Pharma

Technology Development Status: Prototype

Technology Readiness Level: TRL 2

Vetted Programs/Awards: We are currently in the Wisconsin Alumni Research Foundation (WARF) Accelerator Program (AP) and we have received two rounds of funding from the program. We also received funding from the Draper Technology Innovation Funds (TIF).

SHOWCASE SUMMARY

Organization Type: Early-stage Startup (Seed)

Showcase Booth #: 223

Website: https://immutoscientific.com/

GOVT/EXTERNAL FUNDING SOURCES

External Funding to Date: WARF AP Phase I and Phase II funding and Draper TIF funding.